Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
SIUSOM - Division of Urology, Springfield, Illinois, United States
University of California, San Francisco, San Francisco, California, United States
SIUSOM - Division of Urology, Springfield, Illinois, United States
Site CA1025, Oshawa, Ontario, Canada
Site US1060, Raleigh, North Carolina, United States
Site US1067, Houston, Texas, United States
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Korea University Ansan Hospital, Ansan, Korea, Republic of
Pusan National University Hospital, Busan, Korea, Republic of
Children's Hospital of Michigan, Detroit, Michigan, United States
Universitaetsspital-Basel, Basel, Switzerland
Inselspital Bern, Bern, Switzerland
Hopitaux Universitaires de Geneve, Genève 14, Switzerland
St. Joseph's Healthcare Hamilton - McMaster Institute of Urology, Hamilton, Ontario, Canada
Site US00102, Norman, Oklahoma, United States
Site US00122, Greensboro, North Carolina, United States
Site US00112, Los Angeles, California, United States
Site RS38010 Mother and Child Health Care, Belgrade, Serbia
Site BE32009 Univ.Ziekenhuis Antwerpen, Edegem, Belgium
Site PL48001 Pomnik-Centrum Zdrowia Dziecka, Warsaw, Poland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.